Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions Key clinical takeaways: MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations Lenvatinib plus pembrolizumab is a viable option not only...
